Boehringer intends the deal to expand its IPF portfolio, which includes antifibrotic drug Ofev. Credit: © Boehringer Ingelheim.

Boehringer Ingelheim has entered a collaboration and licence agreement to develop South Korea-based Bridge Biotherapeutics’ drug candidate for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).

The compound, called BBT-877, is an autotaxin inhibitor being studied in Phase I clinical trials. It is expected to start Phase II studies next year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In pre-clinical models for fibrosing interstitial lung diseases, BBT-877 yielded positive safety and efficacy data. The compound also showed potential for use in combination with the current standard of care.

Initially, the alliance will work on developing BBT-877 for IPF.

The deal will expand Boehringer’s IPF portfolio, which includes antifibrotic drug Ofev (nintedanib). Ofev has approvals for treating IPF in more than 70 markets, including the US and EU.

Studies found that Ofev slows down disease progression through the reduction of lung function decline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Boehringer Ingelheim Board of Managing Directors member Michel Pairet said: “This new collaboration complements our growing pipeline in fibrosing interstitial lung diseases and is a sign of our determination to bring the next generation of treatment options to these patients.”

Under the agreement, Boehringer will make upfront and near term payments of €45m to Bridge Biotherapeutics, which is also eligible for around €1.1bn in milestone fees.

Bridge Biotherapeutics may also receive royalties.

Earlier this month, Boehringer teamed up with another South Korean company, Yuhan, to develop a dual agonist for nonalcoholic steatohepatitis (NASH) and other related liver disorders.

This deal involves upfront and near-term payments of $40m from Boehringer, along with up to $830m in potential milestones and tiered royalties.